P2Y<sub>2</sub>R‑mediated transactivation of VEGFR2 through Src phosphorylation is associated with ESM‑1 overexpression in radiotherapy‑resistant‑triple negative breast cancer cells

Jin,Hana; Ko,Young Shin; Yun,Seung Pil; Park,Sang Won; Kim,Hye Jung

doi:10.3892/ijo.2023.5521

P2Y₂R‑mediated transactivation of VEGFR2 through Src phosphorylation is associated with ESM‑1 overexpression in radiotherapy‑resistant‑triple negative breast cancer cells

Authors:
- Hana Jin
- Young Shin Ko
- Seung Pil Yun
- Sang Won Park
- Hye Jung Kim
View Affiliations

Affiliations: Department of Pharmacology, College of Medicine, Institute of Health Sciences, Gyeongsang National University, Jinju, Gyeongsangnam‑do 52727, Republic of Korea
Published online on: May 8, 2023 https://doi.org/10.3892/ijo.2023.5521
Article Number: 73

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously reported that radiotherapy‑resistant (RT‑R) triple negative breast cancer (TNBC) cells upregulate the expression of endothelial‑specific molecule‑1 (ESM‑1) compared with TNBC cells. In addition, ESM‑1 is involved in an increased proliferation and invasion of RT‑R‑TNBC cells compared with TNBC cells. It was further identified that, in RT‑R‑TNBC cells, P2Y₂ purinergic receptor (P2Y₂R)‑mediated activation of p21‑activated kinase 1 (PAK1), protein kinase C (PKC), c‑Jun N‑terminal kinase (JNK) and p38 MAPKs is related to ESM‑1 expression via forkhead box O1 (FoxO1) regulation. Notably, it has been reported that P2Y₂R mediates the transactivation of vascular epithelial growth factor receptor 2 (VEGFR2), and VEGFR2 is known to be involved in ESM‑1 expression. Therefore, in the present study, the involvement of VEGFR2 in the P2Y₂R‑mediated ESM‑1 upregulation in RT‑R‑TNBC cells and the relationship between P2Y₂R and VEGFR2 activation was further examined. Western blotting and reverse transcription‑PCR were used to monitor the expression of ESM‑1, and the results demonstrated that extracellular ATP treatment regulated the expression of ESM‑1 in a P2Y₂R‑dependent manner in RT‑R‑MDA‑MB‑231 cells. In addition, extracellular ATP activated Src and VEGFR2 after 5 min of incubation, which was abolished by knockdown of P2Y₂R expression. VEGFR2 activation in response to ATP was also decreased by inhibiting Src activity, suggesting that ATP‑activated P2Y₂R regulates VEGFR2 phosphorylation via Src activation. Furthermore, ATP‑induced ESM‑1 expression was decreased by transfection with VEGFR2 small interfering RNA (siRNA). ESM‑1‑related signaling molecules, PAK1, PKC, JNK and p38 MAPKs, and the transcriptional regulator, FoxO1, which were activated by ATP, were also decreased following transfection with VEGFR2 siRNA. These results suggest that P2Y₂R‑mediated transactivation of VEGFR2 through Src phosphorylation is associated with ESM‑1 overexpression in RT‑R‑TNBC cells.

View Figures

View References

1	Balta S, Balta I and Mikhailidis DP: Endocan: A new marker of endothelial function. Curr Opin Cardiol. 36:462–468. 2021. View Article : Google Scholar : PubMed/NCBI
2	Yang J, Yang Q, Yu S and Zhang X: Endocan: A new marker for cancer and a target for cancer therapy. Biomed Rep. 3:279–283. 2015. View Article : Google Scholar : PubMed/NCBI
3	Yang WE, Hsieh MJ, Lin CW, Kuo CY, Yang SF, Chuang CY and Chen MK: Plasma levels of endothelial cell-specific molecule-1 as a potential biomarker of oral cancer progression. Int J Med Sci. 14:1094–1100. 2017. View Article : Google Scholar : PubMed/NCBI
4	Maurage CA, Adam E, Minéo JF, Sarrazin S, Debunne M, Siminski RM, Baroncini M, Lassalle P, Blond S and Delehedde M: Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol. 68:633–641. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kim JH, Park MY, Kim CN, Kim KH, Kang HB, Kim KD and Kim JW: Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1α in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep. 28:1701–1708. 2012. View Article : Google Scholar : PubMed/NCBI
6	Rocha SF, Schiller M, Jing D, Li H, Butz S, Vestweber D, Biljes D, Drexler HCA, Nieminen-Kelha M, Vajkoczy P, et al: Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ Res. 115:581–590. 2014. View Article : Google Scholar : PubMed/NCBI
7	Spill F, Reynolds DS, Kamm RD and Zaman MH: Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol. 40:41–48. 2016. View Article : Google Scholar : PubMed/NCBI
8	Corriden R and Insel PA: Basal release of ATP: An autocrine-paracrine mechanism for cell regulation. Sci Signal. 3:re12010. View Article : Google Scholar : PubMed/NCBI
9	Di Virgilio F and Adinolfi E: Extracellular purines, purinergic receptors and tumor growth. Oncogene. 36:293–303. 2017. View Article : Google Scholar : PubMed/NCBI
10	Kaur J and Dora S: Purinergic signaling: Diverse effects and therapeutic potential in cancer. Front Oncol. 13:10583712023. View Article : Google Scholar : PubMed/NCBI
11	de Araújo JB, Kerkhoff VV, de Oliveira Maciel SFV and de Resende E Silva DT: Targeting the purinergic pathway in breast cancer and its therapeutic applications. Purinergic Signal. 17:179–200. 2021. View Article : Google Scholar : PubMed/NCBI
12	Gendron FP, Placet M and Arguin G: P2Y₂ receptor functions in cancer: A perspective in the context of colorectal cancer. Adv Exp Med Biol. 1051:91–106. 2017. View Article : Google Scholar : PubMed/NCBI
13	Jin H, Eun SY, Lee JS, Park SW, Lee JH, Chang KC and Kim HJ: P2Y2 receptor activation by nucleotides released from highly metastatic breast cancer cells increases tumor growth and invasion via crosstalk with endothelial cells. Breast Cancer Res. 16:R772014. View Article : Google Scholar : PubMed/NCBI
14	Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
15	Kumar P and Aggarwal R: An overview of triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269. 2016. View Article : Google Scholar : PubMed/NCBI
16	Zhang H, Luo H, Jiang Z, Yue J, Hou Q, Xie R and Wu S: Fractionated irradiation-induced EMT-like phenotype conferred radioresistance in esophageal squamous cell carcinoma. J Radiat Res. 57:370–380. 2016. View Article : Google Scholar : PubMed/NCBI
17	Ko YS, Jin H, Lee JS, Park SW, Chang KC, Kang KM, Jeong BK and Kim HJ: Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells. Oncol Rep. 40:3752–3762. 2018.PubMed/NCBI
18	Jin H, Rugira T, Ko YS, Park SW, Yun SP and Kim HJ: ESM-1 Overexpression is involved in increased tumorigenesis of radiotherapy-resistant breast cancer cells. Cancers (Basel). 12:13632020. View Article : Google Scholar : PubMed/NCBI
19	Jin H and Kim HJ: P2Y2R-mediated PAK1 activation is involved in ESM-1 overexpression in RT-R-MDA-MB-231 through FoxO1 regulation. Cancers (Basel). 14:41242022. View Article : Google Scholar : PubMed/NCBI
20	Seye CI, Yu N, Gonzalez FA, Erb L and Weisman GA: The P2Y2 nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1). J Biol Chem. 279:35679–35686. 2004. View Article : Google Scholar : PubMed/NCBI
21	Liao Z, Cao C, Wang J, Huxley VH, Baker O, Weisman GA and Erb L: The P2Y2 receptor interacts with VE-cadherin and VEGF receptor-2 to regulate Rac1 activity in endothelial cells. J Biomed Sci Eng. 7:1105–1121. 2014. View Article : Google Scholar : PubMed/NCBI
22	Abid MR, Yi X, Yano K, Shih SC and Aird WC: Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res. 72:136–145. 2006. View Article : Google Scholar : PubMed/NCBI
23	Jin H, Lee JS, Kim DC, Ko YS, Lee GW and Kim HJ: Increased extracellular adenosine in radiotherapy-resistant breast cancer cells enhances tumor progression through A2AR-Akt-β-catenin signaling. Cancers. 13:21052021. View Article : Google Scholar : PubMed/NCBI
24	Sham D, Wesley UV, Hristova M and van der Vliet A: ATP-mediated transactivation of the epidermal growth factor receptor in airway epithelial cells involves DUOX1-dependent oxidation of Src and ADAM17. PLoS One. 8:e543912013. View Article : Google Scholar : PubMed/NCBI
25	Ryden L, Linderholm B, Nielsen NH, Emdin S, Jönsson PE and Landberg G: Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat. 82:147–154. 2023. View Article : Google Scholar : PubMed/NCBI
26	Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D, et al: VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 34:3107–3119. 2015. View Article : Google Scholar : PubMed/NCBI
27	Gurdal H, Tuglu MM, Bostanabad SY and Dalkiliç B: Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple-negative breast cancer cell lines. Int J Oncol. 54:1345–1356. 2019.PubMed/NCBI
28	Kolářová I, Melichar B, Vaňásek J, Sirák I, Petera J, Horáčková K, Pohanková D, Šinkorová Z, Hošek O and Vošmik M: Special techniques of adjuvant breast carcinoma radiotherapy. Cancers (Basel). 15:2982022. View Article : Google Scholar : PubMed/NCBI
29	Haussmann J, Corradini S, Nestle-Kraemling C, Bölke E, Njanang FJD, Tamaskovics B, Orth K, Ruckhaeberle E, Fehm T, Mohrmann S, et al: Recent advances in radiotherapy of breast cancer. Radiat Oncol. 15:712020. View Article : Google Scholar : PubMed/NCBI
30	Carlson RW and McCormick B: Update: NCCN breast cancer clinical practice guidelines. J Natl Compr Canc Netw. 3 (Suppl 1):S7–S11. 2005.PubMed/NCBI
31	Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY, Kim CH, Park HG, Han SI and Kang HS: Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol Cancer. 16:102017. View Article : Google Scholar : PubMed/NCBI
32	Gilreath C, Boerma M, Qin Z, Hudson MK and Wang S: The hypoxic microenvironment of breast cancer cells promotes resistance in radiation therapy. Front Oncol. 10:6294222021. View Article : Google Scholar : PubMed/NCBI
33	Joo YN, Jin H, Eun SY, Park SW, Chang KC and Kim HJ: P2Y2R activation by nucleotides released from the highly metastatic breast cancer cell MDA-MB-231 contributes to pre-metastatic niche formation by mediating lysyl oxidase secretion, collagen crosslinking, and monocyte recruitment. Oncotarget. 5:9322–9334. 2014. View Article : Google Scholar : PubMed/NCBI
34	Jin H, Ko YS and Kim HJ: P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer. Int J Oncol. 53:1953–1966. 2018.PubMed/NCBI
35	Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, Rogler A, Stöhr R, Hartmann A, Provenzano M, et al: Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res. 73:1097–1106. 2013. View Article : Google Scholar : PubMed/NCBI
36	Zhang Y and Brekken RA: Direct and indirect regulation of the tumor immune microenvironment by VEGF. J Leukoc Biol. 111:1269–1286. 2022. View Article : Google Scholar : PubMed/NCBI
37	Simons M, Gordon E and Claesson-Welsh L: Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 17:611–625. 2016. View Article : Google Scholar : PubMed/NCBI
38	Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N and Wiegand SJ: Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 15:171–185. 2012. View Article : Google Scholar : PubMed/NCBI
39	Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar : PubMed/NCBI
40	Holmes K, Roberts OL, Thomas AM and Cross MJ: Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 19:2003–2012. 2007. View Article : Google Scholar : PubMed/NCBI
41	Rini BI and Rathmell WK: Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res. 13:741s–746s. 2007. View Article : Google Scholar : PubMed/NCBI
42	Norambuena A, Palma F, Poblete MI, Donoso MV, Pardo E, Gonzalez A and Huidobro-Toro JP: UTP controls cell surface distribution and vasomotor activity of the human P2Y2 receptor through an epidermal growth factor receptor-transregulated mechanism. J Biol Chem. 285:2940–2950. 2010. View Article : Google Scholar : PubMed/NCBI
43	Ratchford AM, Baker OJ, Camden JM, Rikka S, Petris MJ, Seye CI, Erb L and Weisman GA: P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells. J Biol Chem. 285:7545–7555. 2010. View Article : Google Scholar : PubMed/NCBI
44	Liu J, Liao Z, Camden J, Griffin KD, Garrad RC, Santiago-Pérez LI, González FA, Seye CI, Weisman GA and Erb L: Src homology 3 binding sites in the P2Y2 nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors. J Biol Chem. 279:8212–8218. 2004. View Article : Google Scholar : PubMed/NCBI
45	Li WH, Qiu Y, Zhang HQ, Tian XX and Fang WG: P2Y2 receptor and EGFR cooperate to promote prostate cancer cell invasion via ERK1/2 pathway. PLoS One. 10:e01331652015. View Article : Google Scholar : PubMed/NCBI